Join our daily newsletter At The Bell to receive exclusive market insights
- AdAlta (1AD) receives a European patent from the European Patent Office for its lead product AD-124
- The patent is titled “CXCR4 binding molecules” and has an expiry date of January 8, 2036
- It protects the i-body sequence used in AD-214, sequences similar to this and pharmaceutical compositions and derivatives containing the i-body sequences
- AdAlta is now in the process of validating this patent in 18 countries across Europe which is expected to be completed by August 2022
- On market close, 1AD are up four per cent to 5.2 cents per share
Biotechnology company AdAlta (1AD) has been granted a European patent from the European Patent Office for its lead product AD-214.
The patent is titled “CXCR4 binding molecules” and has an expiry date of January 8, 2036.
It protects the i-body sequence used in AD-214, sequences similar to this and pharmaceutical compositions and derivatives containing the i-body sequences.
The patent also protects the use of the sequences in therapeutic and diagnostic applications.
AdAlta is now in the process of validating this patent in 18 countries across Europe which is expected to be completed by August 2022. This will enable the patent to be enforced in each country.
AD-214 now has two patents in Australia and the US, and one in China, India, Japan and Singapore.
“Grant of this European patent means AD-214 now has patent protection until 2036 in the
eight largest pharmaceutical markets in the world: US, Japan, China, Germany, France,
Italy, Spain and UK,” CEO and Managing Director Dr Tim Oldham said.
On market close, 1AD were up four per cent to 5.2 cents per share.
